This US-based key opinion leader (KOL) opines on the current treatment approach in wet AMD. The KOL talks about the current trends in biologics prescription among retina specialists while also discussing the impact of biosimilars and newer therapies. He also adds on the impact of Eylea HD, Susvimo and the potential launch of Lytenava on marketed therapies while also discussing patients’ and payers’ point of view in drug uptake. The KOL also highlights compliance issues, promising pipeline therapies, cost of treatments and what constitutes a well-rounded product for the wet AMD market. 

This interview was conducted on January 13, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.  

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.